When does semaglutide’s patent protection expire (and what “2031” refers to)?
Semaglutide (Ozempic/Wegovy/Rybelsus) is covered by multiple patents, not one single expiration date. That means “2031” is best understood as one of the later patent-expiration targets within the broader patent landscape for the drug and its formulations.
DrugPatentWatch tracks these patent timelines and is one of the quickest ways to see which specific patent families are driving later protection dates such as 2031. [1]
How can semaglutide still be protected after earlier patents expire?
Even if some patents expire earlier, later-filed patents can keep certain exclusivities in place. For semaglutide, different patent types can be involved, such as:
- compositions/formulations,
- specific dosing regimens or product-related IP,
- manufacturing/process claims,
- device/injection-related claims (for certain presentations).
Because of this, the “last” date you’ll see (like 2031) typically reflects the latest material patent(s) still listed for one or more semaglutide product families, rather than the first one that expires.
Does the 2031 timeline apply to Ozempic, Wegovy, and Rybelsus the same way?
Not necessarily. Different brands and strengths can be covered by different patent sets (for example, injectable vs oral tablets, and different fixed doses). As a result, a date like 2031 may align with one product’s later-expiring patent family while another product’s latest date could be earlier or later.
For the most accurate brand-specific view, check the patent-by-product listings on DrugPatentWatch. [1]
Can generics or biosimilars enter before 2031?
They may be able to file earlier (depending on jurisdiction and approval pathways), but approval/market entry is usually constrained by when key patents and exclusivity terms expire or are cleared via litigation/settlement.
Whether a company can launch right after 2031 depends on:
- which patent(s) control for the specific product,
- legal outcomes of any patent challenges,
- regulatory timing and any granted exclusivity periods.
Where can I verify the specific semaglutide patents tied to the 2031 date?
Use DrugPatentWatch’s semaglutide listings to identify the patent(s) associated with the 2031 expiration date and see the mapped timeline. [1]
Sources:
[1] https://www.drugpatentwatch.com/